GROUP ONE TRADING, L.P. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 97 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GROUP ONE TRADING, L.P. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q2 2023$1,371
-6.0%
9720.0%0.00%
Q1 2023$1,458
-95.8%
972
-93.0%
0.00%
Q3 2021$35,000
+250.0%
13,807
+34.3%
0.00%
Q3 2020$10,000
+11.1%
10,2790.0%0.00%
Q2 2020$9,0000.0%10,2790.0%0.00%
Q1 2020$9,000
-40.0%
10,279
-40.2%
0.00%
Q4 2019$15,00017,1790.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$28,160,0003.29%
Defender Capital, LLC. 4,416,590$3,657,0002.67%
Prescott General Partners LLC 1,851,851$1,534,0000.13%
Laidlaw Wealth Management LLC 107,379$89,0000.06%
Northeast Financial Consultants Inc 523,756$434,0000.05%
Beirne Wealth Consulting Services, LLC 45,000$37,0000.04%
DAFNA Capital Management LLC 95,000$79,0000.03%
Summit X, LLC 30,700$25,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 529,039$438,0000.01%
Keudell/Morrison Wealth Management 10,105$8,0000.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders